5-chloro-6-methyl-indoline-2,3-dione | 107583-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-6-methyl-indoline-2,3-dione
• 英文别名: 5-Chlor-6-methyl-indolin-2,3-dion；5-chloro-6-methyl-1H-indole-2,3-dione；5-chloro-6-methylisatin；5-Chloro-6-methylindoline-2,3-dione
• CAS: 107583-35-7
• 化学式: C₉H₆ClNO₂
• 分子量: 195.605
• InChiKey: NWMQLFYENNVRLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-6-methyl-indoline-2,3-dione 在 盐酸 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 6-chloro-3,7-dimethylspiro[1H-quinazoline-4,5'-imidazolidine]-2,2',4'-trione
  参考文献：
  名称：

  Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors

  摘要：

  A series of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones were prepared and tested for aldose reductase inhibitory activity. The 6'-halogenated derivatives were found to be highly potent in vitro inhibitors of male rabbit lens aldose reductase and in vivo inhibitors of polyol accumulation in the sciatic nerves of galactosemic rats. Of these, (4R)-6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione (67) showed the most potent in vitro and in vivo activities. An oral dose of 3 g/kg of compound 67 caused neither death nor behavioral abnormality in the preliminary acute toxicity study using mice and rats. Compound 67 was selected as a candidate for further evaluation. The quantitative structure-activity relationships in this series are also discussed.

  DOI：

  10.1021/jm00089a021
• 作为产物：
  描述：

  4-氯-3-甲基苯胺 在 硫酸 、 硫酸羟胺 作用下， 生成 5-chloro-6-methyl-indoline-2,3-dione
  参考文献：
  名称：

  Sandmeyer, Helvetica Chimica Acta, 1919, vol. 2, p. 239

  摘要：

  DOI：

文献信息

• [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
  申请人：SANKYO CO

  公开号：WO2003106435A1

  公开（公告）日：2003-12-24

  AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

  新化合物具有以下式（I）的结构，其药学上可接受的盐和酯可以调节LXR功能，从而表现出优秀的抗动脉粥样硬化和抗炎活性：其中：A代表芳基或杂环芳基；R1、R2和R3相同或不同，每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-（烷基羰基）-N-（烷基）氨基、烷氧羰基氨基、N-（烷氧羰基）-N-（烷基）氨基、烷磺酰氨基、N-（烷磺酰基）-N-（烷基）氨基、卤代烷基磺酰氨基、N-（卤代烷基磺酰基）-N-（烷基）氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基，或R1和R2一起是亚烷二氧基；R4和R5相同或不同，每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基；X代表氢、羟基、卤素、烷氧基或卤代烷氧基；Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
• Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
  申请人：——

  公开号：US20040180878A1

  公开（公告）日：2004-09-16

  The invention relates to compounds of formula: 1 and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V 1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V 1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  这项发明涉及以下公式的化合物：1，以及与矿物酸或有机酸形成的盐，以及具有亲和力和选择性作用于精氨酸加压素V1b受体和/或催产素受体的溶剂化合物和/或水合物，此外，对于某些化合物，还具有对V1a受体的亲和力。该发明还涉及制备它们的过程，对于制备它们有用的公式（IV）的中间化合物，含有它们的药物组合物以及它们用于制备药品的用途。
• Design and synthesis of isatin derivatives as effective <scp>SARS‐CoV</scp>‐2 <scp>3CL</scp> protease inhibitors
  作者：Hong‐Lei Bao、Gao Tu、Qiu Yue、Pei Liu、Hui‐Li Zheng、Xiao‐Jun Yao

  DOI：10.1111/cbdd.14296

  日期：2023.10

  SARS-CoV-2 chymotrypsin-like cysteine protease (3CLpro) is one of the most widely developed drug targets for COVID-19. This study aimed to design and synthesize isatin derivatives to target SARS-CoV-2 3CLpro in a covalent binding manner. Through the process, a potent 3CLpro inhibitor (5g) was discovered with an IC50 value of 0.43 ± 0.17 μM. To understand the binding affinity and specificity of 5g as

  SARS-CoV-2 胰凝乳蛋白酶样半胱氨酸蛋白酶 (3CL pro ) 是针对 COVID-19 开发最广泛的药物靶点之一。本研究旨在设计和合成靛红衍生物，以共价结合方式靶向 SARS-CoV-2 3CL pro 。通过这个过程，我们发现了一种有效的 3CL前体抑制剂 (5g)，其 IC 50值为 0.43 ± 0.17 μM。为了了解 5g 作为 SARS-CoV-2 3CL pro候选抑制剂的结合亲和力和特异性，进行了多项测定，包括 FRET 酶活性测定、基于热力学和动力学的抑制剂-靶标相互作用验证以及细胞-基于 FlipGFP 的检测。3CL pro之间的相互作用机制-5g通过对接进行了表征。总体而言，这些发现表明 5g 是一种用于治疗 COVID-19 的新型有效 SARS-CoV-2 3CL前体抑制剂。
• AN ANTIMALARIAL ALKALOID FROM HYDRANGEA. XV. SYNTHESIS OF 5-, 6-, 7-, AND 8-DERIVATIVES WITH TWO IDENTICAL SUBSTITUENTS
  作者：B. R. BAKER、ROBERT E. SCHAUB、JOSEPH P. JOSEPH、FRANCIS J. McEVOY、JAMES H. WILLIAMS

  DOI：10.1021/jo01135a015

  日期：1952.1
• YAMADA, YOSHIHISA;MATSUOKA, YUZO;MATSUMOTO, MAMORU
  作者：YAMADA, YOSHIHISA、MATSUOKA, YUZO、MATSUMOTO, MAMORU

  DOI：——

  日期：——